title: Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
abstract: BCL-2 and C-RAF genes are overexpressed in most types of cancers. Although these genes are mediators in different molecular pathways their main characteristic is the antiapoptotic activity, thus cells that overexpress either BCL-2 or C-RAF lose their ability to undergo apoptotic death being resistant to chemotherapeutic agents and/or physiologic mediators of cell death (e.g., TNF-alpha). Both anti-C-RAF, and anti-BCL-2 oligonucleotides were tested as chemosensitizers in cancer therapy. The aim of the study was to investigate the effects of the combined use of antisense oligonucleotides (ASOs) targeting BCL-2 and C-RAF transcripts on the in vitro cancer cell cultures exposed to etoposide. Cells were transfected with phosphorothioate BCL-2 and C-RAF ASOs. To sustain high intracellular level of ASOs, 3-day transfection was used, and it was followed by a single treatment with 20 microM etoposide for 5 h. The following cancer cell lines were tested: A549, HeLa, and T24. Sequence-specific decrease in BCL-2, and C-RAF mRNA levels were confirmed by real-time RT-PCR: after 1-day treatment mRNA levels decreased by 9-42% of the normal expression in cells treated with 50-1200 nM ASOs. Also, the induction of cell death in all transfected cultures in a concentration-dependent manner was confirmed by MTT assay,microscopic analysis of cell morphology, and the measurement of histone H3 expression. Results also showed that both ASOs effectively potentiated etoposide-induced cytotoxicity; the strongest effects were obtained in A549 (lung cancer). This observation suggests that lower concentrations of both antisense oligonucleotides may be used, at least for this type of cancer, to obtain high efficiency of etoposide-induced cell death enhancement. Simultaneous use of two ASOs in 3-day treatment allows us to lower concentrations needed to obtain significant treatment results thus enabling to diminish sequence-unspecific toxicity.
authors.affiliation: Department of Biotechnology and Genetic Engineering, Medical University of Silesia in Katowice, Narcyzów 1, 41-200 Sosnowiec, Poland. dsypniewski@sum.edu.pl
authors.forename: Daniel
authors.initials: D
authors.lastname: Sypniewski
authors.forename: Ilona
authors.initials: I
authors.lastname: Bednarek
authors.forename: Sabina
authors.initials: S
authors.lastname: Gałka
authors.forename: Tomasz
authors.initials: T
authors.lastname: Loch
authors.forename: Daria
authors.initials: D
authors.lastname: Błaszczyk
authors.forename: Dagna
authors.initials: D
authors.lastname: Sołtysik
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D048430:Cell Shape / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005047:Etoposide / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic; D020868:Gene Silencing; D006367:HeLa Cells; D006657:Histones / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D016376:Oligonucleotides, Antisense / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics* / Q000378:metabolism; D019908:Proto-Oncogene Proteins c-raf / Q000235:genetics* / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D014162:Transfection
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D006657:Histones; D016376:Oligonucleotides, Antisense; D019253:Proto-Oncogene Proteins c-bcl-2; D012333:RNA, Messenger; D005047:Etoposide; D019908:Proto-Oncogene Proteins c-raf